ULTRAGENYX PHARMACEUTICAL INC. Debt Securities, Available-for-sale
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Debt Securities, Available-for-sale of $371.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale $371.00M.
- 2026-03-31: Debt Securities, Available-for-sale $454.00M.
- 2025-12-31: Debt Securities, Available-for-sale $665.00M.
- 2025-09-30: Debt Securities, Available-for-sale $368.85M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $371.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $454.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $665.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $368.85M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $479.56M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $510.19M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $696.00M 10-K · filed 2026-02-18 | $695.78M 10-K · filed 2025-02-19 |
| 2024-09-30 | $775.47M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $832.65M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $536.69M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $735.82M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $495.81M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $593.41M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $689.99M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $876.63M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $975.07M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $677.48M 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $791.58M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $968.31M 10-K · filed 2023-02-17 | |
| 2020-12-31 | $1.17B 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |